One thing Cellceutix has done is taken the time to do smaller studies to better target their drugs. With these results brings better opportunity to present for a better deal. We need that $15M to be closer to $100M. I cringe when I see companies realign their shelf registration to astronomical #'s like a 250M shelf. It happens all the time though and then the dilution is almost endless, but that's what they need to do to survive as a start up - mid stage pre-revenue.
I don't think we'll need to worry about such a tiny upfront with either Prurisol or Brilacidin. I would be shocked if we saw less than $50M upfront for either. Our shelf already is in place for $75M if we need it. Even if we used it all it's not dilution in my book if it adds greater value to the company. Financing is certainly nothing to worry about here.
All content of my posts is my opinion and speculation. Do not treat anything I say as fact or actionable investment advice. I participate to challenge my investment thesis from any angle possible. Please do your own due diligence.